Johnson & Johnson recently partnered with Global Citizen, a social action platform, to improve the trajectory of human health on a global scale, granting each individual the chance to have a healthy future.
The U.S. Preventive Services Task Force (USPSTF) recently conducted new studies to evaluate scientific evidence and found that routine screening for genital herpes using blood tests is not supported with evidence.
The U.S. Food and Drug Administration (FDA) recently approved of marketing for two new computerized cognitive tests to determine a person’s cognitive functioning after receiving a suspected concussion or brain injury.
The U.S. Food and Drug Administration (FDA) recently stated that there was sufficient evidence of a novel investigational oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 to begin phase III clinical studies.
The National Institutes of Health (NIH) recently funded a worldwide study that suggests surgically removing the thymus gland from patients with myasthenia gravis can bring about positive outcomes for the patients.
The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), recently found that approximately 80 percent of preschool children with peanut allergies had positive responses to oral immunotherapy.
The Partnership to Fight Chronic Disease (PFCD) recently launched the Federal Communications Commission’s (FCC’s) Connect2Health Task Force (C2H), which is dedicated to the new Mapping Broadband Health in America technology.
Leaders with the U.S. Food and Drug Administration recently released a proposed rule to ask for more scientific data to support the efficacy and safety of various active ingredients that are added to hand sanitizers.
Officials with the U.S. Food and Drug Administration recently granted approval of the Raindrop Near Vision Inlay, a device that can be implanted into the cornea to resolve nearsightedness for patients who have presbyopia.
A team of researchers at the National Institutes of Health (NIH) recently developed a new drug that shows promise for limiting liver fibrosis progression in mice, which may prove useful for humans as well.